Pelthos Therapeutics Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended June 30, 2026, the following director and officers terminated a “Rule 10b5-1 trading arrangement” as is defined in Item 408(a) of Regulation S-K:
| Name | Title | Date of Termination | Date of Adoption | Aggregate Number of Securities Subject to the Arrangement (1) |
|---|---|---|---|---|
| Richard Malamut | Director | May 7, 2026 | December 12, 2025 | 5,761 |
| Scott Plesha | Chief Executive Officer | June 15, 2026 | December 12, 2025 | 26,542 |
| John M. Gay | Chief Financial Officer | June 15, 2026 | December 12, 2025 | 9,739 |
| Sai Rangarao | Chief Commercial Officer | June 29, 2026 | December 12, 2025 | 10,098 |
(1) As of the date of termination, Dr. Malamut had sold 590 shares of Common Stock pursuant to the terms of Mr. Malamut’s Rule 10b5-1 trading arrangement. As of the date of termination, our officers had not sold any shares of Common Stock pursuant to the terms of their Rule 10b5-1 trading arrangements.
Other than as disclosed above, during the three months ended June 30, 2026, no director or officer adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.